GlassScriptPhysician profile
Robert Claflin
NPI 1164959441
$2,612.41
in general payments reported to CMS, 2019-2025
27 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.81 · 2022: $626 · 2023: $726 · 2024: $538 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $388.29 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $374.40 | 2021-2025 | Vraylar |
| Grt US Holding, INC. | $284.96 | 2022 | |
| Angiodynamics, INC. | $216.85 | 2023 | Auryon Laser System 100-120 Vac |
| Novo Nordisk INC | $176.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $171.78 | 2021-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $159.78 | 2023-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $152.44 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Medtronic, INC. | $119.05 | 2024 | Inceptiv |
| Averitas Pharma INC. | $83.60 | 2024-2025 | Qutenza |
| Biotronik INC. | $76.93 | 2023 | Pulsar-18 T3 |
| Shield Therapeutics INC | $65.20 | 2022-2025 | |
| Cleerly, INC. | $41.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Impulse Dynamics (USA) INC. | $38.16 | 2022-2024 | Optimizer |
| Abbott Laboratories | $35.79 | 2022-2023 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.53 | 2021-2022 | |
| Pfizer INC. | $29.57 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $18.82 | 2022 | |
| Baxter Healthcare | $18.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.30 | 2025 | Voquezna |
| Exact Sciences Corporation | $16.48 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.08 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $15.91 | 2025 | Xtampza |
| Bardy Diagnostics, INC. | $15.32 | 2022 | |
| Amgen INC. | $14.42 | 2022 | |
| Horizon Therapeutics Plc | $13.02 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Claflin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.